Antiphospholipid antibodies are associated with an incinsufficiency in patients with lupus nephritis

American Journal of Kidney Diseases 43, 28-36

DOI: 10.1053/j.ajkd.2003.09.011

Citation Report

#	Article	IF	CITATIONS
1	Coagulopathies and the kidney. Lupus, 2004, 13, 765-768.	1.6	0
2	Management of Lupus Nephritis: An Update. Journal of the American Society of Nephrology: JASN, 2004, 15, 2694-2704.	6.1	69
3	Perspectives on the changing face of lupus mortality. Autoimmunity Reviews, 2004, 3, 415-417.	5.8	5
4	Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus. Lupus, 2004, 13, 869-876.	1.6	12
7	Rein et lupus : données récentes. Revue Du Rhumatisme (Edition Francaise), 2005, 72, 162-167.	0.0	1
8	Class III–IV Proliferative Lupus Nephritis and Pregnancy: A Study of 42 Cases. American Journal of Reproductive Immunology, 2005, 53, 182-188.	1.2	71
9	Diagnosis and treatment of kidney disease. Best Practice and Research in Clinical Rheumatology, 2005, 19, 785-798.	3.3	26
10	The Long-Term Prognosis of Renal Transplantation in Patients With Lupus Nephritis. American Journal of Kidney Diseases, 2005, 45, 903-911.	1.9	119
11	The Course of Anticardiolipin Antibody Levels Under Immunoadsorption Therapy. American Journal of Kidney Diseases, 2005, 46, 446-454.	1.9	15
12	Renal transplantation in lupus nephritis. Lupus, 2005, 14, 95-98.	1.6	58
13	Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?. Nature Clinical Practice Rheumatology, 2005, 1 , 22-30.	3.2	25
14	Factors associated with poor outcomes in patients with lupus nephritis. Lupus, 2005, 14, 890-895.	1.6	165
15	Prognostic factors in lupus nephritis. Lupus, 2005, 14, 39-44.	1.6	119
16	Lupus Nephritis. Seminars in Nephrology, 2006, 26, 95-104.	1.6	20
17	Kidney Disease in Antiphospholipid Syndrome. Rheumatic Disease Clinics of North America, 2006, 32, 509-522.	1.9	45
18	International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 2006, 4, 295-306.	3.8	6,039
19	Kidney Disease in Antiphospholipid Syndrome. , 2006, , 99-111.		1
21	Lupus nephritis and renal disease in pregnancy. Lupus, 2006, 15, 148-155.	1.6	87

#	Article	IF	Citations
22	Clinical importance of autoantibodies in lupus nephritis. Expert Review of Clinical Immunology, 2007, 3, 937-947.	3.0	3
23	Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology, 2007, 47, 183-187.	1.9	60
24	African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Annals of the Rheumatic Diseases, 2007, 66, 618-622.	0.9	42
25	New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Reviews in Molecular Medicine, 2007, 9, 1-15.	3.9	31
26	Antiphospholipid Syndrome in Systemic Lupus Erythematosus. Journal of the American Society of Nephrology: JASN, 2007, 18, 2461-2464.	6.1	29
27	The Antiphospholipid Syndrome. Seminars in Nephrology, 2007, 27, 35-46.	1.6	39
28	Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies. Nephrology, 2007, 12, 474-480.	1.6	40
29	Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatric Nephrology, 2007, 22, 222-231.	1.7	72
31	Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clinical Rheumatology, 2008, 27, 345-351.	2.2	41
32	EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Annals of the Rheumatic Diseases, 2008, 67, 195-205.	0.9	645
33	Novel therapies for the antiphospholipid syndrome. Expert Review of Clinical Immunology, 2008, 4, 193-203.	3.0	1
34	Thrombotic Microangiopathy and Renal Failure Exacerbated by Îμ-Aminocaproic Acid. American Journal of Kidney Diseases, 2009, 53, 346-350.	1.9	7
35	Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2009, 36, 109-125.	6.5	30
36	Renal Involvement in the Antiphospholipid Syndrome (APS)—APS Nephropathy. Clinical Reviews in Allergy and Immunology, 2009, 36, 131-140.	6.5	96
37	Management of the antiphospholipid syndrome: new approaches. International Journal of Clinical Rheumatology, 2009, 4, 533-549.	0.3	2
38	Beyond immunosuppression – challenges in the clinical management of lupus nephritis. Lupus, 2009, 18, 106-115.	1.6	27
39	An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nature Reviews Nephrology, 2009, 5, 132-142.	9.6	39
40	Clinical approach to lupus nephritis: Recent advances. European Journal of Internal Medicine, 2009, 20, 447-453.	2.2	35

3

#	Article	IF	Citations
41	Thrombosis in systemic lupus erythematosus: risk and protection. Expert Review of Cardiovascular Therapy, 2009, 7, 1541-1549.	1.5	30
42	Statins for the Treatment of Antiphospholipid Syndrome?. Annals of the New York Academy of Sciences, 2009, 1173, 736-745.	3.8	49
43	Management of lupus nephritis—current perspectives. Indian Journal of Rheumatology, 2009, 4, 153-161.	0.4	0
44	The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity, 2009, 42, 257-259.	2.6	38
45	Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Current Opinion in Rheumatology, 2009, 21, 495-500.	4.3	54
46	Antiphospholipid Antibodies and Renal Outcomes in Patients with Lupus Nephritis. Internal Medicine, 2009, 48, 1875-1880.	0.7	12
47	Lupus Nephritis. American Journal of the Medical Sciences, 2009, 337, 451-460.	1.1	32
49	Severe Vascular Lesions and Poor Functional Outcome in Kidney Transplant Recipients with Lupus Anticoagulant Antibodies. American Journal of Transplantation, 2010, 10, 2051-2060.	4.7	71
51	Predictors of poor renal outcome in patients with biopsyâ€proven lupus nephritis. Nephrology, 2010, 15, 482-490.	1.6	69
52	What nephrologists need to know about antiphospholipid syndrome. Nephrology Dialysis Transplantation, 2010, 25, 3147-3154.	0.7	43
53	Lupus Nephritis. , 2010, , 308-321.		4
54	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Annals of the Rheumatic Diseases, 2010, 69, 1269-1274.	0.9	308
55	Severe paediatric systemic lupus erythematosus nephritis-a single-centre experience. Nephrology Dialysis Transplantation, 2010, 25, 457-463.	0.7	12
56	Renal Involvement in Primary Antiphospholipid Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1211-1217.	4.5	83
57	Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus, 2010, 19, 557-574.	1.6	185
58	Oxidative stress and homocysteine metabolism in patients with lupus nephritis. Lupus, 2010, 19, 65-72.	1.6	37
59	Treatment of proliferative lupus nephritis: a slowly changing landscape. Nature Reviews Nephrology, 2011, 7, 96-109.	9.6	33
60	SÃndrome antifosfolÃpidos. EMC - Aparato Locomotor, 2011, 44, 1-20.	0.1	0

#	ARTICLE	IF	CITATIONS
61	IgM Anti-ß2Glycoprotein I Is Protective Against Lupus Nephritis and Renal Damage in Systemic Lupus Erythematosus. Journal of Rheumatology, 2011, 38, 450-453.	2.0	45
62	Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrology Dialysis Transplantation, 2011, 26, 620-627.	0.7	15
63	Recurrence of Secondary Glomerular Disease after Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1214-1221.	4.5	58
64	Geriatric Rheumatology. , 2011, , .		6
65	Antiphospholipid syndrome-associated nephropathy in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2012, 7, 131-134.	0.3	2
66	Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. Rheumatology, 2012, 51, 663-669.	1.9	18
68	Communications affichees. Revue Du Rhumatisme (Edition Francaise), 2012, 79, A133-A334.	0.0	0
71	Recurrence of glomerulonephritis after renal transplantation. Transplantation Reviews, 2013, 27, 126-134.	2.9	38
73	Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim. Lupus, 2013, 22, 504-509.	1.6	11
74	Outcomes in renal transplant recipients with lupus nephritis: experience at a single center. Renal Failure, 2014, 36, 912-915.	2.1	5
75	End-stage Renal Disease Due to Membranous Lupus Nephritis: Is Antiphospholipid Syndrome Misdiagnosed or Underestimated?. Journal of Nephrology & Therapeutics, 2014, 04, .	0.1	0
76	4G/5G plasminogen activator inhibitor-1 and â^'308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis. Clinical and Experimental Medicine, 2014, 14, 83-89.	3.6	7
77	Prognostic Factors for Treatment Response in Patients With Lupus Nephritis. ReumatologÃa ClÃnica (English Edition), 2014, 10, 164-169.	0.3	3
78	Renal involvement in antiphospholipid syndrome. Nature Reviews Nephrology, 2014, 10, 279-289.	9.6	84
79	Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatology International, 2014, 34, 535-541.	3.0	22
80	Predictores de respuesta al tratamiento en pacientes con nefritis lúpica. ReumatologÃa ClÃnica, 2014, 10, 164-169.	0.5	7
81	A Case of Thrombotic Microangiopathy Associated With Antiphospholipid Antibody Syndrome Successfully Treated With Eculizumab. Transplantation, 2014, 98, e17-e18.	1.0	25
82	The impact of antiphospholipid antibodies in children with lupus nephritis. International Journal of Pediatrics and Adolescent Medicine, 2015, 2, 147-151.	1.2	5

#	Article	IF	CITATIONS
83	Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. Lupus, 2015, 24, 331-338.	1.6	26
85	Antiphospholipid Syndrome and the Kidney. Seminars in Nephrology, 2015, 35, 478-486.	1.6	66
86	Pregnancy and Lupus Nephritis. Seminars in Nephrology, 2015, 35, 487-499.	1.6	85
87	The national incidence and clinical picture of SLE in children in Australia – a report from the Australian Paediatric Surveillance Unit. Lupus, 2015, 24, 66-73.	1.6	24
88	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5. 6	40
89	Renal involvement in primary antiphospholipid syndrome. Journal of Nephrology, 2016, 29, 507-515.	2.0	10
90	Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study. Rheumatology, 2016, 55, 817-825.	1.9	9
91	Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus, 2017, 26, 1564-1570.	1.6	24
92	The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of Autoimmunity, 2017, 76, 10-20.	6.5	146
93	Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. Nephrology Dialysis Transplantation, 2018, 33, 709-716.	0.7	13
94	Antiphospholipid Antibody Positivity and the Clinical Outcomes of Patients with Systemic Lupus Erythematosus. Journal of Rheumatic Diseases, 2018, 25, 239.	1.1	3
95	Diagnostic and prognostic role of renal histopathology in rheumatic diseases. Reumatismo, 2018, 70, 165-177.	0.9	3
96	Renal Involvement in Antiphospholipid Syndrome. Frontiers in Immunology, 2018, 9, 1008.	4.8	32
97	Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Frontiers in Immunology, 2018, 9, 1181.	4.8	52
98	Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome. PLoS ONE, 2018, 13, e0196172.	2.5	0
99	Renal involvement in antiphospholipid syndrome. Rheumatology International, 2018, 38, 1777-1789.	3.0	17
100	Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. Lupus, 2019, 28, 1460-1467.	1.6	6
101	The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer, 2019, 19, 841.	2.6	55

#	Article	IF	CITATIONS
102	Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Advances in Chronic Kidney Disease, 2019, 26, 376-386.	1.4	21
103	Antiphospholipid Antibodies in Patients with Membranous Nephropathy. Nephron, 2019, 143, 228-233.	1.8	4
104	Renal Function Affects Prognostic Role of Antiphosphatidylserine Antibodies for Acute Ischemic Stroke Patients. Cerebrovascular Diseases, 2019, 48, 1-8.	1.7	2
105	Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. Lupus Science and Medicine, 2019, 6, e000308.	2.7	8
106	Association between antiphospholipid antibodies and factor Bb in lupus nephritis patients with glomerular microthrombosis. International Journal of Rheumatic Diseases, 2019, 22, 2185-2190.	1.9	4
107	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1004-1006.	0.9	23
108	Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis. Clinical Rheumatology, 2020, 39, 1531-1535.	2.2	6
109	Lupus nephritis. Nature Reviews Disease Primers, 2020, 6, 7.	30.5	416
111	Update on Lupus Nephritis: Looking for a New Vision. Nephron, 2021, 145, 1-13.	1.8	49
112	Association of antiphospholipid antibodies with clinical activity and renal pathological activity in patients with lupus nephritis. Lupus, 2021, 30, 1140-1145.	1.6	3
113	Clinical Features and Treatment of Systemic Lupus Erythematosus. , 2009, , 1263-1300.		8
114	Antiphospholipid Antibodies in Lupus Nephritis. PLoS ONE, 2016, 11, e0158076.	2.5	26
115	Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia, 2012, 32 Suppl 1, 1-35.	0.4	24
116	Renal Disease in Systemic Lupus Erythematosus With Emphasis on Classification of Lupus Glomerulonephritis: Advances and Implications. Archives of Pathology and Laboratory Medicine, 2009, 133, 233-248.	2.5	85
117	Vaskulitiden und Systemerkrankungen. , 2008, , 417-505.		0
118	Glomerular, Vascular, and Tubulo-Interstitial Diseases. , 2008, , 237-285.		0
122	Task Force Report on Non-criteria Manifestations: Nephropathy. , 2012, , 207-221.		1
123	Symmetrical Peripheral Gangrene ComplicatingEscherichia coliSepsis Associated with Antiphospholipid Antibodies in Lupus Nephritis. Korean Journal of Medicine, 2014, 87, 379.	0.3	0

#	Article	IF	Citations
124	Update on systemic lupus erythematosus pregnancy. Journal of Prenatal Medicine, 2010, 4, 67-73.	0.2	12
125	Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmunity Reviews, 2022, 21, 103158.	5.8	10
126	Severe lupus nephritis in the present days., 0, 2, .		1
127	Renal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy. Journal of Autoimmunity, 2022, 132, 102889.	6.5	4
129	Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus. Rheumatology and Therapy, 2023, 10, 7-34.	2.3	8
130	A Clinical Approach of Lupus Nephritis Associated with Catastrophic Antiphospholipid - Antibody Syndrome - Review and Case Report. Medicina Interna (Bucharest, Romania: 1991), 2022, 19, 77-87.	0.0	O
131	Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). CKJ: Clinical Kidney Journal, 0, , .	2.9	O
132	Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis. Nefrologia, 2023, , .	0.4	2
133	Antiphospholipid syndrome nephropathy: Current knowledge and unanswered questions. Clinical Immunology, 2023, 255, 109735.	3.2	1
134	Antiphospholipid syndrome and kidney involvement. Kidney and Blood Pressure Research, 0, , .	2.0	O
135	Anti-phospholipid autoantibodies in human diseases. Clinical Immunology, 2023, 256, 109803.	3.2	1
136	Bibliometric analysis of lupus nephritis in children from 1999 to 2022: A review. Medicine (United) Tj ETQq $1\ 1\ 0$.	784314 rş	gBT _O Overlock
137	Kidney transplantation: the recipient., 2024,, 411-691.		O
138	The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. Rheumatology, 2024, 63, SI72-SI85.	1.9	1
139	Anticardiolipin Antibody Plays a More Important Role Than Anti- \hat{I}^2 2-Glycoprotein I Antibody in Activating Complement in Patients with Lupus Nephritis. International Journal of General Medicine, 0, Volume 17, 517-523.	1.8	0